FINCH 1: 52-Wk Results of Filgotinib in Patients With Rheumatoid Arthritis With Inadequate Response to Methotrexate

June 3-6, 2020; Virtual Meeting
Efficacy of add-on therapy with JAK1 inhibitor filgotinib sustained through Week 52 with no new safety signals in patients with rheumatoid arthritis and inadequate response to methotrexate.
Format: Microsoft PowerPoint (.ppt)
File Size: 231 KB
Released: July 13, 2020

Acknowledgements

Provided by Clinical Care Options, LLC

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com

Supported by an educational grant from
AbbVie Inc.
Gilead Sciences, Inc.

Related Content

Stanley B. Cohen, MD, answers questions about the ACR 2020 Pharmacologic Recommendations for the management of RA.

Stanley B. Cohen, MD Released: December 23, 2020

From ACR/ARP 2020: expert-authored commentary on tapering RA therapy, as reported by Clinical Care Options (CCO)

Jonathan Kay, MD Physicians: maximum of 0.25 AMA PRA Category 1 Credits Released: December 18, 2020 Expired: December 17, 2021

Maria Danila, MD, MSc, MSPH Physicians: maximum of 0.25 AMA PRA Category 1 Credits Released: December 18, 2020 Expired: December 17, 2021

Safety: Frequently asked questions from the CCO Webinar series, “ A Closer Look at Evolving Treatment Strategies for Rheumatoid Arthritis”

Stanley B. Cohen, MD Sheetal Desai, MD, MSEd Eric M. Ruderman, MD Released: December 18, 2020

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue